Potential Therapy for Individuals with Copper Metabolism Disorders: Study

Individuals with copper metabolism disorders may soon get possible treatment alternative where they can make use of more targeted treatment.

More targeted treatment options can be made available for individuals with copper metabolism defects, reports a new study. The findings of the study are published in the journal Proceedings of the National Academy of Sciences.//

Elesclomol, an investigational anticancer-drug can restore a critical copper-dependent enzyme called cytochrome oxidase protein complex required for mitochondrial energy production.

Copper Deficiency | Hypocupremia - Causes, Symptoms, Diagnosis, Treatment, and Prevention
Copper is an essential trace element in the body for maintaining good health. However, copper deficiency can cause a wide variety of symptoms, usually due to underlying disease conditions.

‘New discovery may point to targeted therapy for people with copper metabolism disorders. Elesclomol, an anticancer-drug may help restore a critical copper-dependent enzyme for mitochondrial energy production.’

The discovery is vital since copper is an essential trace metal necessary for survival. Copper is found in all body tissues and plays a critical role in a variety of physiological processes, including energy production, detoxification of harmful free radicals, connective tissue maturation, neurotransmitter biosynthesis and brain development.

Copper metabolism deficiencies have been linked to genetic disorders such as Menkes disease, which affects infants and young children and result in deterioration of the nervous system and failure to develop fully.

The research was led by Gohil, an associate professor in the department of biochemistry and biophysics at Texas A&M University in College Station, and his graduate student, Shivatheja Soma, who worked collaboratively with scientists at the Marine Biological Laboratory, the University of Maryland, the University of Saskatchewan in Canada and the Department of Drug Discovery and Biomedical Sciences in South Carolina.

Chelation Therapy - Benefits, Side Effects & Health Tips
The process of removing heavy metals from the body is known as Chelation Therapy. Learn more about the medical procedure of chelation therapy.

"Copper is an essential micronutrient required for mitochondrial energy production," Gohil said. "Inherited mutations that prevent copper delivery to a key mitochondrial enzyme perturb energy production and result in fatal mitochondrial disease. Currently, no therapy exists for these disorders."

Gohil said a prior attempt to treat patients with these mutations by direct copper supplementation was not successful, possibly because of inefficient copper delivery to the mitochondria.

Wilson's Disease
This is a rare inherited systemic disorder of copper metabolism, affecting the liver mainly before other organs.

"Through a targeted search for copper-binding compounds, we identified elesclomol, an investigational anti-cancer drug, as the most efficient copper delivery agent," he said.

The study utilized multiple model organisms to test the efficacy of elesclomol in rescuing copper deficiency. In particular, a zebrafish model of copper deficiency developed by Dr. Andrew Latimer, a research scientist at the Marine Biological Laboratory in Massachusetts, was vital in showing the efficacy of elesclomol in a vertebrate animal. Additionally, the authors directly demonstrated the therapeutic potential of elesclomol in human patient cells with genetic mutations that impair copper delivery to cytochrome oxidase.

Therapeutic Drug Monitoring - Importance, Guidelines, Indications & Limitations
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's bloodstream to maintain it within a therapeutic window.

The research involved testing several copper-binding pharmacological agents for their ability to restore mitochondrial function in a yeast model. Among these compounds, they found elesclomol was unique in that it was efficacious at low nanomolar concentrations without exhibiting overt toxicity at higher concentrations.

According to the scientists, these findings reveal that elesclomol can mimic the missing transporters of copper, which provide the potential opportunity to treat human disorders of copper metabolism.

"Elesclomol has undergone multiple human clinical trials. Thus our findings offer an exciting possibility of repurposing this anti-cancer drug for the treatment of copper metabolism disorders," Gohil said.

Source-Eurekalert